Sumner County committee discusses OD maps, synthetic opioids and testing gaps

Sumner County Opioid Event Committee · February 20, 2026

Get AI-powered insights, summaries, and transcripts

Subscribe
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Committee members reviewed overdose‑mapping options and data privacy limits, noted recent local fatalities, and raised concerns about synthetic opioids and limited local forensic testing that may hide emerging threats.

Members of Sumner County's Opioid Event Committee discussed overdose mapping, data sharing and emerging synthetic opioids during a meeting at the County Administration Building.

Staff described work with Wilson County to obtain an OD‑map template and said the county can produce quarterly heat maps or district maps but cannot show pinpoint locations because of HIPAA and data‑privacy limits. A committee member suggested using Rutherford County's near‑real‑time data or other external sources that update more frequently than quarterly exports.

Committee members also reported two overdose fatalities in the past week and reviewed which commission districts have recent higher counts. Several speakers raised concern about newly circulating synthetics and the limits of Middle Tennessee laboratory testing; the transcript records that Knox County laboratories are testing for new variants while many local labs are not yet able to test comprehensively, which can delay identification of new, highly potent analogs.

Staff and members discussed how federal supply‑side enforcement that reduced prescription availability contributed to shifts toward illicit heroin and fentanyl and how newer fentanyl analogs can be substantially more potent than historic opioids. Committee discussion included operational points such as the need for updated toxicology testing and the importance of targeting naloxone distribution and treatment referrals to identified hot spots.

The committee assigned the drug task force to discuss OD maps at its next meeting and flagged the limits of current local testing capacity as a priority for coordination with regional forensics.